Back to Search
Start Over
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach.
- Source :
-
Diabetologia [Diabetologia] 2024 Sep; Vol. 67 (9), pp. 1817-1827. Date of Electronic Publication: 2024 Jun 05. - Publication Year :
- 2024
-
Abstract
- Aims/hypothesis: Older adults are under-represented in trials, meaning the benefits and risks of glucose-lowering agents in this age group are unclear. The aim of this study was to assess the safety and effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in people with type 2 diabetes aged over 70 years using causal analysis.<br />Methods: Hospital-linked UK primary care data (Clinical Practice Research Datalink, 2013-2020) were used to compare adverse events and effectiveness in individuals initiating SGLT2i compared with dipeptidyl peptidase-4 inhibitors (DPP4i). Analysis was age-stratified: <70 years (SGLT2i n=66,810, DPP4i n=76,172), ≥70 years (SGLT2i n=10,419, DPP4i n=33,434). Outcomes were assessed using the instrumental variable causal inference method and prescriber preference as the instrument.<br />Results: Risk of diabetic ketoacidosis was increased with SGLT2i in those aged ≥70 (incidence rate ratio compared with DPP4i: 3.82 [95% CI 1.12, 13.03]), but not in those aged <70 (1.12 [0.41, 3.04]). However, incidence rates with SGLT2i in those ≥70 was low (29.6 [29.5, 29.7]) per 10,000 person-years. SGLT2i were associated with similarly increased risk of genital infection in both age groups (incidence rate ratio in those <70: 2.27 [2.03, 2.53]; ≥70: 2.16 [1.77, 2.63]). There was no evidence of an increased risk of volume depletion, poor micturition control, urinary frequency, falls or amputation with SGLT2i in either age group. In those ≥70, HbA <subscript>1c</subscript> reduction was similar between SGLT2i and DPP4i (-0.3 mmol/mol [-1.6, 1.1], -0.02% [0.1, 0.1]), but in those <70, SGLT2i were more effective (-4 mmol/mol [4.8, -3.1], -0.4% [-0.4, -0.3]).<br />Conclusions/interpretation: Causal analysis suggests SGLT2i are effective in adults aged ≥70 years, but increase risk for genital infections and diabetic ketoacidosis. Our study extends RCT evidence to older adults with type 2 diabetes.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Aged
Female
Male
United Kingdom epidemiology
Aged, 80 and over
Hypoglycemic Agents therapeutic use
Hypoglycemic Agents adverse effects
Diabetic Ketoacidosis epidemiology
Diabetic Ketoacidosis chemically induced
Treatment Outcome
Middle Aged
Sodium-Glucose Transporter 2 Inhibitors therapeutic use
Sodium-Glucose Transporter 2 Inhibitors adverse effects
Diabetes Mellitus, Type 2 drug therapy
Dipeptidyl-Peptidase IV Inhibitors therapeutic use
Dipeptidyl-Peptidase IV Inhibitors adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1432-0428
- Volume :
- 67
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Diabetologia
- Publication Type :
- Academic Journal
- Accession number :
- 38836934
- Full Text :
- https://doi.org/10.1007/s00125-024-06190-9